Your browser doesn't support javascript.
loading
Self-assembled peptide-paclitaxel nanoparticles for enhancing therapeutic efficacy in colorectal cancer.
Hou, Lidan; Zhong, Ting; Cheng, Peng; Long, Bohan; Shi, Leilei; Meng, Xiangjun; Yao, Han.
Afiliação
  • Hou L; Department of Gastroenterology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Zhong T; The Digestive Disease Research and Clinical Transformation Center, Shanghai Jiao Tong University, Shanghai, China.
  • Cheng P; Shanghai Key Laboratory of Gut Microecology and Associated Diseases, Shanghai, China.
  • Long B; Department of Gastroenterology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Shi L; The Digestive Disease Research and Clinical Transformation Center, Shanghai Jiao Tong University, Shanghai, China.
  • Meng X; Shanghai Key Laboratory of Gut Microecology and Associated Diseases, Shanghai, China.
  • Yao H; Department of Gastroenterology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Front Bioeng Biotechnol ; 10: 938662, 2022.
Article em En | MEDLINE | ID: mdl-36246349
ABSTRACT
Chemotherapy is one of the main treatments for colorectal cancer, but systemic toxicity severely limits its clinical use. Packaging hydrophobic chemotherapeutic drugs in targeted nanoparticles greatly improve their efficacy and reduce side effects. We previously identified a novel colorectal cancer specific binding peptide P-LPK (LPKTVSSDMSLN) from phage display peptide library. Here we designed a self-assembled paclitaxel (PTX)-loaded nanoparticle (LPK-PTX NPs). LPK-PTX NPs displayed a superior intracellular internalization and improved tumor cytotoxicity in vitro. Cy5.5-labeled LPK-PTX NPs showed much higher tumor accumulation in colorectal cancer-bearing mice. Furthermore, LPK-PTX NPs exhibit enhanced antitumor activity and decreased systemic toxicity in colorectal cancer patient-derived xenografts (PDX) model. The excellent in vitro and in vivo antitumor efficacy proves the improved targeting drug delivery, suggesting that peptide P-LPK has potential to provide a novel approach for enhanced drug delivery with negligible systemic toxicity.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Bioeng Biotechnol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Bioeng Biotechnol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China